@article{ref1,
title="Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a real-world chart review study",
journal="Revista brasileira de psiquiatria",
year="2020",
author="De Berardis, Domenico and Fornaro, Michele and Anastasia, Annalisa and Vellante, Federica and Olivieri, Luigi and Rapini, Gabriella and Serroni, Nicola and Orsolini, Laura and Valchera, Alessandro and Department of Mental HealthCarano, Alessandro and Tomasetti, Carmine and Ventriglio, Antonio and Bustini, Massimiliano and Pompili, Maurizio and Serafini, Gianluca and Perna, Giampaolo and Iasevoli, Felice and Martinotti, Giovanni and di Giannantonio, Massimo",
volume="42",
number="3",
pages="317-321",
abstract="OBJECTIVE: Selective serotonin reuptake inhibitors (SSRIs) are the cornerstone of treatment of major depressive disorder (MDD). However, non-response is common, often necessitating combination strategies. The present study assessed the efficacy of vortioxetine as an add-on therapy in patients with SSRI-resistant MDD. <br><br>METHODS: The charts of 36 adult outpatients with DSM-IV-TR MDD who had not achieved a response after at least 8 weeks of treatment with an SSRI were reviewed retrospectively. Subjects were treated with vortioxetine (5-20 mg/day) for 8 weeks added to the current SSRI. The main outcome measures were change from baseline in total Hamilton Scale for Depression (HAM-D) score and the rate of response (a 50% or greater reduction in HAM-D score and a Clinical Global Impression &#8208; Improvement module [CGI-I] score of 1 or 2 at endpoint). HAM-D scores &#8804; 7 were considered as remission. Additional outcome measures included the Snaith-Hamilton Pleasure Scale (SHAPS) and the Scale for Suicide Ideation (SSI). <br><br>RESULTS: 32 patients completed the 8 weeks of treatment. At 8 weeks, a significant reduction in HAM-D score was observed (p &#8804; 0.001), with response obtained by 41.7% and remission by 33.3% of patients. Significant reductions in SHAPS and SSI were also observed (p &#8804; 0.001 for both scales). <br><br>CONCLUSIONS: Adjunctive vortioxetine may be useful and well-tolerated in stage I treatment-resistant depression. However, the limitations of this study (such as small sample size, absence of randomization and control group, retrospective design, etc.) must be considered.<p /><p>Language: en</p>",
language="en",
issn="1516-4446",
doi="10.1590/1516-4446-2019-0690",
url="http://dx.doi.org/10.1590/1516-4446-2019-0690"
}